1-2 of 2
Matthew A. Arquette
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Free
Paula M. Fracasso, Howard Burris, III, Matthew A. Arquette, Ramaswamy Govindan, Feng Gao, Lisa P. Wright, Sherry A. Goodner, F. Anthony Greco, Suzanne F. Jones, Noel Willcut, Catherine Chodkiewicz, Amit Pathak, Gregory M. Springett, George R. Simon, Daniel M. Sullivan, Raphaël Marcelpoil, Shelley D. Mayfield, David Mauro, Christopher R. Garrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 986–993.
https://doi.org/10.1158/1078-0432.CCR-06-1542
Published: 08 February 2007
View articletitled, A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Open the PDF for A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing in another window
Journal Articles

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

Free
Paula M. Fracasso, Lori J. Goldstein, Dinesh P. de Alwis, Janet S. Rader, Matthew A. Arquette, Sherry A. Goodner, Lisa P. Wright, Carole L. Fears, Robert J. Gazak, Valerie A. M. Andre, Michael F. Burgess, Christopher A. Slapak, Jan H. M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7220–7228.
https://doi.org/10.1158/1078-0432.CCR-04-0452
Published: 08 November 2004
View articletitled, Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
Open the PDF for Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies in another window